Publications by authors named "P Roessner"

Claim this Profile
A
Absorption, Metabolism, Distribution and Excretion (ADME) and Absolute Bioavailability Assessment of Zongertinib in Healthy Male Volunteers.
Rolf Grempler, David Joseph, Guanfa Gan, Adam M Auclair, Renger G Tiessen, Philipp M Roessner

Clin Drug Investig· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Relative Bioavailability of Zongertinib, an Orally Administered HER2-Selective Tyrosine Kinase Inhibitor, under Fed and Fasted Conditions in Healthy Male Participants: Results from Two Randomized, Open-Label, Crossover Studies.
Hélène Pereira, Stefan Wölke, Behbood Sadrolhefazi, Habib Esmaeili, Sven Wind, Philipp M Roessner

Mol Pharm· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The effect of carbamazepine, a strong CYP3A inducer, on the pharmacokinetics of zongertinib in healthy male volunteers.
Xiaofan Tian, Habib Esmaeili, David Minich, Friedeborg Seitz, Philipp M Roessner

Pharmacotherapy· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Longitudinal omics data and preclinical treatment suggest the proteasome inhibitor carfilzomib as therapy for ibrutinib-resistant CLL.
Lavinia Arseni, Gianluca Sigismondo, Haniyeh Yazdanparast, Johanne U Hermansen, Norman Mack, Philipp M Roessner

Nat Commun· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CD20-bispecific antibodies improve response to CD19-CAR T cells in lymphoma in vitro and CLL in vivo models.
Berit J Brinkmann, Alessia Floerchinger, Christina Schniederjohann, Tobias Roider, Mariana Coelho, Philipp M Roessner

Blood· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis